RBC Capital raised the firm’s price target on HCA Healthcare (HCA) to $555 from $525 and keeps an Outperform rating on the shares. The firm was “pleased” to see a strong reaction in shares after a solid Q4 result and strong initial 2026 guidance, the analyst tells investors in a research note. The 2026 full year outlook reflects better than expected core performance as well as $400M in savings from resiliency efforts that more than offset the ePTC expiry and lower contribution from state supplemental programs, RBC added.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $529 from $490 at TD Cowen
- HCA Healthcare price target raised to $598 from $525 at UBS
- HCA Healthcare price target raised to $540 from $500 at Oppenheimer
- HCA Healthcare price target raised to $588 from $525 at Cantor Fitzgerald
- HCA Healthcare price target raised to $550 from $500 at KeyBanc